Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

Diabetic foot gel linked to increased cancer risk

Discussion in 'Diabetic Foot & Wound Management' started by NewsBot, Mar 27, 2008.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    Reuters are reporting:
    Cancer risk seen with J&J foot gel: FDA
    Thu Mar 27, 2008 4:54pm EDT
    Link to story
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Here is the FDA statement on this:
    Communication about an Ongoing Safety Review Regranex (becaplermin)
     
  3. Admin2

    Admin2 Administrator Staff Member

  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    We initially missed this, here is the companies response to the FDA concerns from March 27:

    Press Release:
    BioMimetic Therapeutics Addresses FDA Communication on Regranex Safety Review
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Update

    Press Release from the FDA:
    FDA Announces New Labeling Changes for Regranex
    Product to carry boxed warning

    Link to FDA press release

    Press Release from Johnson and Johnson:
    ETHICON, INC. Announces Revised Label For REGRANEX® (becaplermin) Gel 0.01%
    CNN are reporting:
     
  6. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Here some marketing spin, just received in the inbox from J & J:
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Becaplermin gel in the treatment of diabetic neuropathic foot ulcers.
    Papanas N, Maltezos E.
    Clin Interv Aging. 2008;3(2):233-40.
     
  8. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf. 2010 Jun 1;33(6):455-61.
     
Loading...

Share This Page